-

Model N and Global Pricing Innovations Announce Strategic Partnership

Life Sciences Technology Leaders to Deliver Scalable Solution Enabling Best-in-Class, Data-Powered Insights Around International Pricing and Market Access Decision-Making

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced a strategic life sciences industry partnership with Global Pricing Innovations (GPI), a market leader in analytics, insights and innovative solutions that help life sciences companies achieve day-to-day operational improvement and market access excellence. The partnership with Model N delivers scalable technology and services that enable data-powered insights, achieving measurable impact on global customer pricing and market access decision-making.

Management of international customer pricing and market access is key to effective pharmaceutical pricing strategies. The collaboration between Model N and GPI combines the Model N Revenue Cloud for Life Sciences with GPI’s data and consulting services, delivering value in the form of global pricing strategies that provide measurable revenue benefits for companies across life sciences. Customers will leverage Model N’s industry-leading capabilities in global price management and international reference pricing, combined with GPI’s pricing data and analytics.

According to Melonie Warfel, vice president and general manager of Life Sciences for Model N, the GPI partnership underscores Model N’s commitment to providing customers with industry- leading analytics to make critical decisions and achieve market access excellence. “We are dedicated to providing life sciences firms with tools that provide the best in decision-making information when it comes to global pricing and market access,” she said. “And this new partnership with GPI – a recognized leader in their space – provides customers with a seamless end-to-end experience that enables them to manage pricing data and derive optimal strategies through a single, deeply-integrated solution.”

GPI is a market leader in analytics and innovative solutions for biopharma pricing and market access, supporting price decision-making throughout the lifecycle. As a team of leading domain specialists, GPI provides high-quality, curated insights and recommendations on global drug pricing strategy, market access optimization, asset evaluation, value perception, and payer behaviour. “Our new partnership with Model N delivers the best of both worlds to clients seeking an enhanced solution for biopharma pricing and market access,” said Preeti Patel, GPI CEO. “Users of Model N Revenue Cloud can now leverage GPI’s critical competitor insights and solutions in order to achieve optimized global pricing that drives profitable revenue.”

About Model N

Model N enables life sciences and high tech companies to drive growth and market share, minimizing revenue leakage throughout the revenue lifecycle. With deep industry expertise and solutions purpose-built for these industries, Model N delivers comprehensive visibility, insight and control over the complexities of commercial operations and compliance. Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom and Microchip Technology. For more information, visit www.modeln.com.

About GPI

GPI is a market leader in analytics and innovative solutions for biopharma pricing and market access. Headquartered London, with offices in Cambridge and Mumbai, GPI supports price decision-making throughout the lifecycle and helps the industry achieve day-to-day operational improvement and market access excellence.

As a team of leading domain specialists, GPI provides high quality, curated insights and recommendations on global drug pricing strategy, market access optimisation, asset evaluation, value perception and payer behaviour. GPI’s suite of technology and bespoke service offerings are powered by GPI pulse™, a solution that harnesses the power of technology, data, and collective expertise to drive effective and efficient access to medicines with faster insights and sustainable pricing strategies. To find out more about GPI, visit www.globalpricing.com.

Contacts

Media Contact:
Denyse Dabrowski
Bospar Public Relations
denyse@bospar.com

Investor Relations Contact:
Gwyn Lauber
Model N, Inc.
investorrelations@modeln.com
650-610-4998

Media Contact:
Jamie Cant
Marketing Manager
jamie.cant@globaplpricing.com

Model N, Inc.

NYSE:MODN

Release Versions

Contacts

Media Contact:
Denyse Dabrowski
Bospar Public Relations
denyse@bospar.com

Investor Relations Contact:
Gwyn Lauber
Model N, Inc.
investorrelations@modeln.com
650-610-4998

Media Contact:
Jamie Cant
Marketing Manager
jamie.cant@globaplpricing.com

Social Media Profiles
More News From Model N, Inc.

Vista Equity Partners Completes Acquisition of Model N

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced the completion of its acquisition by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses, for $30.00 per share in cash in a transaction that values the Company at approximately $1.25 billion. With the completion of the transaction, Model...

Model N Launches Channel Collaboration to Strengthen Visibility for High-Tech Manufacturers and Their Channel Partners

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), the leader in revenue optimization and compliance today announced the launch of Channel Collaboration, a new self-service portal for high-tech manufacturers and their channel partners. Channel Collaboration provides high-tech manufacturers and their partners real-time visibility into channel data, enabling faster and more informed business decisions while maintaining channel compliance. "Channel collaboration plays a pivotal role in the...

Model N Responds to Mounting Regulatory Pharma Pressures with Innovations that Ensure Compliance and Optimize Revenue

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), the leader in revenue optimization and compliance today announced new product innovations geared towards the increasingly complex regulatory environment for global pharma manufacturers. Model N’s latest product enhancements relating to 340B, the Inflation Reduction Act (IRA), and global pricing help pharma manufacturers effectively manage duplicate discounts and maintain compliance with evolving U.S. and international regulations. Contin...
Back to Newsroom